Endocrinology

Help Shape the Future of Denosumab Treatment

As biosimilars enter the denosumab landscape, your perspective as a healthcare provider is critical in understanding what factors influence treatment decisions. This brief survey explores your views on reimbursement considerations, coding challenges, switching comfort, and drivers of biosimilar choice. As a thank you, by completing the survey, you’ll be entered into a drawing for a chance to win a $200 gift card.

Take the survey now and make your voice heard

Latest News

Lilly’s Oral GLP-1 Orforglipron Meets End Points in Phase 3 Obesity and Diabetes Trial
Lilly’s Oral GLP-1 Orforglipron Meets End Points in Phase 3 Obesity and Diabetes Trial

August 26th 2025

Patients taking orforglipron achieved significant weight loss, hemoglobin A1c reduction, and cardiometabolic benefits in the phase 3 ATTAIN-2 study, supporting upcoming global regulatory submissions.

What Do Individuals With Obesity Want in am "Ideal" Primary Care Visit? image credit ©Coloures-Pic/stock.adobe.com
What Do Individuals With Obesity Want in an "Ideal" Primary Care Visit?

August 26th 2025

FDA Clears First Over-The-Counter CGM for Weight Management From Signos / image credit ©lukszczepanski/stock.adobe.com
Signos Wins Clearance for First Over-The-Counter CGM for Weight Management

August 25th 2025

In Adults With Obesity, GLP-1 Receptor Agonists May Reduce Risk for Certain Cancer / image credit Jian Bian, PhD, MS  Courtesy of the Regenstrief Institute
In Adults With Obesity, GLP-1 Receptor Agonists May Reduce Risk for Cancer

August 22nd 2025

Excess Intake of Ultraprocessed Foods Tied to Higher Cardiometabolic Risk: Daily Dose / image credit: ©New Africa/AdobeStock
Excess Intake of Ultraprocessed Foods Tied to Higher Cardiometabolic Risk: Daily Dose

August 22nd 2025

Latest CME Events & Activities

More News

© 2025 MJH Life Sciences

All rights reserved.